I'll post this piece in its entirety here.  I think it is worth the read.

Adult skin cells turned to pluripotent stem cells without a cancer-causing agent.
David Cyranoski
Naturenews Published online 30 November 2007 | Nature |
doi:10.1038/news.2007.219

Shinya Yamanaka of Kyoto University in Japan has followed the announcement last week of his startling success in turning human skin cells to embryo-like stem cells, by reporting that he has done the same without the cancer-causing agent used in his original recipe.

The work brings scientists perhaps one step closer to the goal of being to use patient-matched stem cells for therapy.

Yamanaka first demonstrated his method for *reprogramming* cells in mice. Last year he showed that he could produce pluripotent cells - cells that can turn into any of the roughly 220 cell types in the body - by using retroviruses to carry four genes into mouse skin cells1. The four genes reprogrammed the mouse cells to a state similar to those in the early embryo. He named the cells induced pluripotent stem (iPS) cells. But one of those genes, c-myc, is known as an oncogene, which can
cause cancer. When Yamanaka produced live mice from embryos injected with these pluripotent cells, 20% of them developed tumours.

When last week Yamanaka reported similar success using human cells2, the announcement was tempered by the fact that such cells, made using c-myc, would pose a danger to transplant recipients.

In the further work published by Nature Biotechnology today, Yamanaka shows that he can make both human and mouse iPS cells with just three factors, without using c-myc.

Last week James Thomson of the University of Wisconsin in Madison and his colleagues also reported a success with four factors that did not include c-myc4. But Thomson's result needs further work. He created his pluripotent cells using fetal not adult cells, whereas medical applications will require that adult cells be used. And Thomson's method has not tested in mice, he says. "We've tested these cells in mice and we know they are safe," says Yamanaka.

Before any pluripotent cells will be ready for use in human transplant therapies, however, much more work needs to be done. To reduce risks to recipients, the introduced genes may have to be eliminated altogether, perhaps by simulating their function with a small molecule, or the genes will have to be introduced in a way that does not require viral vectors.

References
1. Takahashi, K. & Yamanaka, S. Cell. 126, 663-676 (2006).
2. Takahashi, K. et al. Cell 131, 861-872
doi:10.1016/j.cell.2007.11.019 (2007).
3. Nakagawa M. et al, Nature Biotechnol. doi: 10.1038/nbt1374 (2007).
4. Yu, J. et al. Science doi: 10.1126/science.1151526 (2007).

Author Profile

Jennifer Lahl, CBC Founder
Jennifer Lahl, CBC Founder
Jennifer Lahl, MA, BSN, RN, is founder and president of The Center for Bioethics and Culture Network. Lahl couples her 25 years of experience as a pediatric critical care nurse, a hospital administrator, and a senior-level nursing manager with a deep passion to speak for those who have no voice. Lahl’s writings have appeared in various publications including Cambridge University Press, the San Francisco Chronicle, the Dallas Morning News, and the American Journal of Bioethics. As a field expert, she is routinely interviewed on radio and television including ABC, CBS, PBS, and NPR. She is also called upon to speak alongside lawmakers and members of the scientific community, even being invited to speak to members of the European Parliament in Brussels to address issues of egg trafficking; she has three times addressed the United Nations during the Commission on the Status of Women on egg and womb trafficking.